APOLLO Study for EPP & XLP – Now Recruiting!

Recruiting-Clinical
Written By United Porphyrias

Participant recruitment is now underway for the APOLLO Study, a clinical trial evaluating Bitopertin, an investigational oral medication for individuals with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP). The study aims to assess whether Bitopertin can reduce protoporphyrin IX levels and potentially lessen symptoms from sun exposure.

Fast Facts:

  • Study Type: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled

  • Who Can Participate? Individuals age 12+ with a confirmed diagnosis of EPP or XLP

  • Study Medication: Investigational oral therapy (Bitopertin)

  • Study Sites: U.S. sites opening soon

  • Travel & related expenses covered by the study sponsor

  • Includes an optional open-label extension

If you are interested, please click here to submit a confidential interest form and be connected to a site near you. Filling out the form does not obligate you to participate.

For more information, contact us at:

Phone: 800-868-1292
Email: info@porphyria.org

Help us spread the word and advance research for the EPP & XLP community!

United Porphyrias
Next

ELEVATE, a Registry of Patients With AHP